Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
1.
Sci Rep ; 12(1): 6862, 2022 04 27.
Artículo en Inglés | MEDLINE | ID: mdl-35477949

RESUMEN

The rates of both maternal and fetal adverse outcomes increase significantly with higher body mass index. The aim of this study was to calculate national estimates of adverse maternal and fetal outcomes and associated hospitalization cost among obese pregnant women using a national database. This study was a retrospective analysis of data retrieved from Nationwide Inpatient Sample database, collected during 2010-2014. The primary outcomes of this study were adverse maternal and fetal outcomes, hospital length of stay, and hospitalization cost. There was a total of 18,687,217 delivery-related hospitalizations, of which 1,048,323 were among obese women. Obese women were more likely to have cesarean deliveries (aOR 1.70, 95% CI 1.62-1.79) and labor inductions (aOR 1.51, 95% CI 1.42-1.60), greater length of stay after cesarean deliveries (aOR 1.14, 95% CI 1.08-1.36) and vaginal deliveries (aOR 1.48, 95% CI 1.23-1.77). They were also more likely to have pregnancy-related hypertension, preeclampsia, gestational diabetes, premature rupture of membranes, chorioamnionitis, venous thromboembolism, excessive fetal growth, and fetal distress. Obese pregnant women had significantly greater risk for adverse obstetrical outcomes, which substantially increased the hospital and economic burden. Risk stratification of pregnant patients based on obesity could also help obstetricians to make better clinical decisions and improve patient outcomes.


Asunto(s)
Preeclampsia , Complicaciones del Embarazo , Femenino , Hospitalización , Humanos , Obesidad/complicaciones , Obesidad/epidemiología , Embarazo , Complicaciones del Embarazo/epidemiología , Resultado del Embarazo/epidemiología , Mujeres Embarazadas , Estudios Retrospectivos , Estados Unidos/epidemiología
3.
Med Clin (Barc) ; 135(11): 485-90, 2010 Oct 09.
Artículo en Inglés | MEDLINE | ID: mdl-20673682

RESUMEN

BACKGROUND AND OBJECTIVES: To assess the use of the Epstein-Barr virus (EBV) viral load as a marker for lymphoma diagnosis in HIV-infected patients. We also aimed to identify the relationship between EBV viral load in plasma and the presence of EBV in lymphoma cells. PATIENTS AND METHODS: Retrospective observational study of two HIV-infected populations: one of patients diagnosed with lymphoma and a control group. Thirty-nine patients with AIDS-related lymphoma (ARL) (32 non-Hodgkin's and 7 Hodgkin's lymphomas) and 134 HIV-positive individuals without neoplasia or opportunistic infections were studied. Blood samples were collected before lymphoma treatment in ARL patients. EBV viral load was measured in plasma by real-time quantitative PCR and the presence of EBV-EBER mRNA in lymphoma tumor was investigated by in situ hybridization. RESULTS: Patients with ARL had higher EBV viral loads than those without lymphoma: 24,180.5 (±73,387.6)copies/mL versus 2.6 (±21.6)copies/mL (p<0.001). HIV-infected patients without lymphoma had negative or very low EBV load values. Among ARL patients, no correlation was found between EBV viral loads and CD4+ lymphocyte counts or between EBV and HIV RNA loads, or any other clinical or biological parameter. Cases with an EBV-EBER-positive lymphoma had higher EBV viral loads than those with EBER-negative tumors. CONCLUSIONS: EBV viral load is a useful marker of lymphoma in HIV-infected patients, and may be a useful tool for early diagnosis and treatment.


Asunto(s)
Herpesvirus Humano 4 , Linfoma Relacionado con SIDA/sangre , Linfoma Relacionado con SIDA/diagnóstico , Carga Viral , Adulto , Biomarcadores/sangre , Femenino , Humanos , Linfoma Relacionado con SIDA/virología , Masculino , Estudios Retrospectivos
5.
Inflamm Bowel Dis ; 14(10): 1373-9, 2008 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-18452205

RESUMEN

BACKGROUND: Cytomegalovirus (CMV) infection has been reported in ulcerative colitis (UC), especially in severe, steroid-refractory disease. However, its role in steroid-refractoriness remains unknown. Our goals were to evaluate the prevalence of CMV disease in UC, the best diagnostic strategy, and the influence of disease activity and/or treatment in its development. METHODS: Prospective, observational study including 114 subjects with active UC requiring intravenous steroids, steroid-refractory UC, inactive UC on mesalamine, inactive UC on azathioprine, and healthy controls. CMV antibodies, pp65-antigenemia, and rectal biopsies for hematoxylin and eosin staining, immunohistochemistry, and CMV-pp67 mRNA were performed. These procedures were repeated after medical treatment only in patients with active UC. CMV disease was defined by the presence of inclusion bodies and/or positive immunohistochemistry in colonic biopsies. RESULTS: CMV disease was found in 6 steroid-refractory, CMV-IgG-positive UC patients but not among controls, inactive UC, or steroid-responding UC patients. In 5 out of the 6 patients, CMV disease was diagnosed after 7-10 days on cyclosporine. CONCLUSIONS: CMV disease in UC only affects seropositive, steroid-refractory UC patients. Steroid/cyclosporine treatment together with disease activity may predispose to latent colonic CMV reactivation. The impact of antiviral therapy on the clinical outcome of these patients remains to be elucidated.


Asunto(s)
Colitis Ulcerosa/epidemiología , Colitis Ulcerosa/virología , Infecciones por Citomegalovirus/diagnóstico , Infecciones por Citomegalovirus/epidemiología , Adulto , Anciano , Anciano de 80 o más Años , Anticuerpos Antivirales/sangre , Estudios de Casos y Controles , Colitis Ulcerosa/diagnóstico , Colitis Ulcerosa/tratamiento farmacológico , Comorbilidad , Ciclosporina/uso terapéutico , Citomegalovirus/inmunología , Citomegalovirus/aislamiento & purificación , Diagnóstico Diferencial , Resistencia a Medicamentos , Femenino , Humanos , Inmunohistoquímica , Masculino , Persona de Mediana Edad , Prevalencia , Estudios Prospectivos , Índice de Severidad de la Enfermedad , Esteroides/uso terapéutico , Adulto Joven
6.
Am J Public Health ; 98(1): 28-38, 2008 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-18048802

RESUMEN

Healthy People 2010 made it a priority to eliminate health disparities. We used a rapid assessment response and evaluation (RARE) to launch a program of participatory action research focused on health disparities in an urban, disadvantaged Black community serviced by a major south Florida health center. We formed partnerships with community members, identified local health disparities, and guided interventions targeting health disparities. We describe the RARE structure used to triangulate data sources and guide intervention plans as well as findings and conclusions drawn from scientific literature and epidemiological, historic, planning, clinical, and ethnographic data. Disenfranchisement and socioeconomic deprivation emerged as the principal determinants of local health disparities and the most appropriate targets for intervention.


Asunto(s)
Agentes Comunitarios de Salud/educación , Redes Comunitarias/organización & administración , Participación de la Comunidad , Disparidades en Atención de Salud/estadística & datos numéricos , Calidad de la Atención de Salud , Servicios Urbanos de Salud/estadística & datos numéricos , Florida , Grupos Focales , Humanos , Proyectos Piloto , Pobreza , Servicios Urbanos de Salud/economía , Población Urbana
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...